标题
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
作者
关键词
Gastric cancer, Chemotherapy, Metastases, Consensus, Recommendation
出版物
Gastric Cancer
Volume 17, Issue 2, Pages 213-225
出版商
Springer Nature
发表日期
2013-09-18
DOI
10.1007/s10120-013-0297-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
- (2012) V. S. Warneke et al. ANNALS OF ONCOLOGY
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
- (2012) Salah-Eddin Al-Batran et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
- (2012) Kensei Yamaguchi et al. Gastric Cancer
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Rafael Lozano et al. LANCET
- Salvage chemotherapy in gastric cancer—more than a straw?
- (2012) Florian Lordick Nature Reviews Clinical Oncology
- Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
- (2011) S. Iqbal et al. ANNALS OF ONCOLOGY
- Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Birgit Luber et al. BMC CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
- (2011) Wasaburo Koizumi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges
- (2011) Florian Lordick Clinical & Translational Oncology
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy
- (2011) Iain Beehuat Tan et al. GASTROENTEROLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
- (2010) N C Tebbutt et al. BRITISH JOURNAL OF CANCER
- A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
- (2010) Jina Yun et al. EUROPEAN JOURNAL OF CANCER
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Population-based differences in treatment outcome following anticancer drug therapies
- (2010) Brigette BY Ma et al. LANCET ONCOLOGY
- A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
- (2009) M. Moehler et al. ANNALS OF ONCOLOGY
- Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
- (2009) W. Koizumi et al. ANNALS OF ONCOLOGY
- Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
- (2009) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
- (2009) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Is there a role for second-line chemotherapy in advanced gastric cancer?
- (2009) Robert Wesolowski et al. LANCET ONCOLOGY
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) S.-E. Al-Batran et al. ANNALS OF ONCOLOGY
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More